Back to top
more

Pharvaris (PHVS)

(Delayed Data from NSDQ)

$35.32 USD

35.32
478,863

-1.68 (-4.54%)

Updated Aug 28, 2026 04:00 PM ET

After-Market: $35.33 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

by Zacks Equity Research

PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.

Zacks Equity Research

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

by Zacks Equity Research

Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

Zacks Equity Research

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

by Zacks Equity Research

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Zacks Equity Research

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.

Zacks Equity Research

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Zacks Equity Research

Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at an 88.2% upside potential for Pharvaris N.V. (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Zacks Equity Research

Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AllScripts Healthcare (MDRX) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.